Iori Biotech and Tavotek Biopharmaceutical Company Establish Strategic R & D Alliance

Release date: 2020-01-06 Views: 0

Source: PR Newswire

Essen Biopharmaceutical Co., Ltd. and Tavotek Biopharmaceutical Co., Ltd. jointly announced that the two parties have reached a R & D strategic alliance to jointly develop a multi-target immune anti-cancer drug combination based on YS-ON-001 / 002 and Tavo-301 / 303. Yisheng Biopharmaceutical Co., Ltd. is a multinational biopharmaceutical company that integrates research and development, production and sales of new immunological macromolecular drugs and vaccine products; Tavotek is a company focusing on the development of new multispecific antibodies for tumors and itself Innovative biopharmaceutical company for immune diseases. The two sides also disclosed that they are negotiating new macromolecular biopharmaceutical cooperation projects outside the field of oncology.

Tavotek has an excellent R & D team and has established a rich pipeline of multispecific antibody products, advanced anti-tumor and other technology platforms in the field of treatment. YS-ON-001 and YS-ON-002, developed by Yisheng Company, are agonists of multiple pathways of TLR3, RIG-I, and MDA5, which can effectively activate the body's innate and adaptive immune responses at the same time, and regulate the tumor microenvironment. And show good safety and tolerance in long-term use. Through the combination with multispecific antibody drugs, it is expected to greatly improve the response rate and overall survival of cancer patients, and develop the world's leading new anti-cancer drug.

YS-ON-001 / 002 is a therapeutic biological product developed by Bio-Bio based on the exclusive PIKA immunomodulation technology platform. These biological macromolecular drugs can kill the immune system through the pathways such as TLR3, RIG-I and MDA5. At the same time, tumor cells inhibit the immunosuppressive state in the tumor microenvironment. YS-ON-001 has entered the clinical development stage in China and Singapore. The product has also been granted the orphan drug qualification of the United States FDA for the treatment of pancreatic and liver cancer. At present, this product has obtained the product number of the Ministry of Health of Cambodia for the treatment of advanced solid tumors. YS-ON-002 already has the conditions for applying for clinical development. YS-ON-001 / 002 can be combined with the current mainstream tumor treatment programs, including chemotherapy, targeted drugs, checkpoint inhibitors and other immunotherapy, to enhance the synergy and effectiveness of drug treatment.

Tavo-301 / 303 is a new generation of immunospecific anti-cancer drugs with multispecific characteristics developed by Tavotek based on its unique TavoSelectTM platform. Through the TavoSelectTM platform, Tavotek's R & D personnel design, construct and optimize the molecular structure of multispecific antibodies, and simultaneously target multiple relevant epitopes to regulate the immune activation / inhibition pathway to achieve effective curative effects on tumor growth. The functions of the TavoSelectTM technology platform also include the advantages of optimizing the pharmacokinetics and stability of protein macromolecules, simplifying the later development of drugs, and optimizing the production process of products.

recommended article

Hunter QR code